Business Segments Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Equities
600329
CNE000001808
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.70 CNY | -1.09% |
|
-1.02% | -10.78% |
| Mar. 31 | Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Drops 4.4% in 2025 | MT |
| Mar. 31 | Singapore Shares Remain in Red Amid Soaring Energy Costs; Rex International Plunges 20% | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Medicinal Chemicals and Botanical Products | ||||||||||
Chinese Patent Medicine | 4.67B | 5.65B | 5.84B | 5.66B | 4.46B | |||||
Healthcare Referral Services | ||||||||||
Others | 627M | 796M | 673M | 443M | 366M | |||||
Pharmaceutical Products | ||||||||||
Western Medicine | 1.6B | 1.78B | 1.7B | 1.19B | 89.94M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
China | 6.86B | 8.2B | 8.16B | 7.26B | 4.87B | |||||
Overseas | 33.91M | 33.74M | 44.88M | 36.73M | 47.8M |
Select your edition
All financial news and data tailored to specific country editions
